KRAS and cancer: In their original research (1), the authors were looking for a potential KRAS epitope for use in targeted cancer immunotherapy in the form of an HLA-presented peptide that would have the following three properties: i) cover the KRAS G12V mutation; ii) be a result of peptide digestion and splicing in the proteasome; iii) bind to HLA-A*02:01.